Literature DB >> 22342575

A framework to evaluate the effects of small area variations in healthcare infrastructure on diagnostics and patient outcomes of rare diseases based on administrative data.

Tom Stargardt1, Jonas Schreyögg.   

Abstract

INTRODUCTION: Small area variations in healthcare infrastructure may result in differences in early detection and outcomes for patients with rare diseases.
METHODS: It is our aim to provide a framework for evaluating small area variations in healthcare infrastructure on the diagnostics and health outcomes of rare diseases. We focus on administrative data as it allows (a) for relatively large sample sizes even though the prevalence of rare diseases is very low, and (b) makes it possible to link information on healthcare infrastructure to morbidity, mortality, and utilization.
RESULTS: For identifying patients with a rare disease in a database, a combination of different classification systems has to be used due to usually multiple diseases sharing one ICD code. Outcomes should be chosen that are (a) appropriate for the disease, (b) identifiable and reliably coded in the administrative database, and (c) observable during the limited time period of the follow-up. Risk adjustment using summary scores of disease-specific or comprehensive risk adjustment instruments might be preferable over empirical weights because of the lower number of variables needed.
CONCLUSION: The proposed framework will help to identify differences in time to diagnosis and treatment outcomes across areas in the context of rare diseases.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22342575     DOI: 10.1016/j.healthpol.2012.01.011

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  1 in total

1.  The collective impact of rare diseases in Western Australia: an estimate using a population-based cohort.

Authors:  Caroline E Walker; Trinity Mahede; Geoff Davis; Laura J Miller; Jennifer Girschik; Kate Brameld; Wenxing Sun; Ana Rath; Ségolène Aymé; Stephen R Zubrick; Gareth S Baynam; Caron Molster; Hugh J S Dawkins; Tarun S Weeramanthri
Journal:  Genet Med       Date:  2016-09-22       Impact factor: 8.822

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.